131515-02-1

Basic information

• Product Name: 5-methyl-6-(3-methylpent-2-en-4-yn-1-yl)-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one
• CAS NO: 131515-02-1
• Molecular Formula: C₁₇H₁₉N₃O
• Molecular Weight: 281.3523
• Mol File: 131515-02-1.mol
• Article Data: 1

Chemical Properties

• Density: 1.23g/cm³
• Refractive Index: 1.643
• CAS DataBase Reference: 5-methyl-6-(3-methylpent-2-en-4-yn-1-yl)-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methyl-6-(3-methylpent-2-en-4-yn-1-yl)-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one(131515-02-1)
• EPA Substance Registry System: 5-methyl-6-(3-methylpent-2-en-4-yn-1-yl)-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one(131515-02-1)

Safety Data

• Hazardous Substances Data: 131515-02-1(Hazardous Substances Data)

Upstream product

• 69371-58-0 (E)-1-bromo-3-methylpent-2-en-4-yne 
• 126233-79-2 4,5,6,7-tetrahydro-5-methylimidazo<4,5,1-jk><1,4>benzodiazepin-2(1H)-one 
• 131514-77-7 methyl 3-nitro-2-<<2-<(phenylmethyl)amino>propyl>amino>benzoate 
• 126234-15-9 2,3,4,5-tetrahydro-3-methyl-9-nitro-4-(phenylmethyl)-1H-1,4-benzodiazepin-5-one 
• 5337-09-7 2-bromo-3-nitro-benzoic acid methyl ester 
• 573-54-6 2-bromo-3-nitro-benzoic acid 
• 6286-36-8 2-bromo-3-nitrobenzoic acid chloride 
• 126233-82-7 4,5,6,7-tetrahydro-5-methyl-6-(phenylmethyl)imidazo<4,5,1-jk><1,4>benzodiazepin-2-(1H)-one 
• 131514-79-9 2,3,4,5-tetrahydro-3-methyl-4-(phenylmethyl)-1H-1,4-benzodiazepin-9-amine 

Relevant articles and documents

Synthesis and Anti-HIV-1 Activity of 4,5,6,7-Tetrahydro-5-methylimidazobenzodiazepin-2(1H)-one (TIBO) Derivatives

A series of 6-substituted 4,5,6,7-tetrahydro-5-methylimidazobenzodiazepin-2(1H)-ones (9) have been synthesized and tested for their ability to inhibit the replication of the HIV-1 virus in MT-4 cells.Two synthetic methods are described, one of which allows the synthesis of single enantiomers of the final products.A structure-activity study was done within the series of compounds to determine the optimum group for the 6-position substitution and to determine whether the activity was enantiospecific at the 5-position, which was substituted with a methyl group.The best analogue, 9jj, inhibited HIV-1 with an IC50 of 4 μM, which is comparable to the activity level of DDI, a 2',3'-dideoxynucleoside-type structure undergoing clinical trials as an anti-AIDS therapy.